Publications: DR Gunnel Hallden

Phillips MM, Pavlyk I, Allen M, Ghazaly E, Cutts R, Carpentier J, Berry JS, Nattress C et al. ( 2023 ) . Correction: A role for macrophages under cytokine control in mediating resistance to ADI-PEG20 (pegargiminase) in ASS1-deficient mesothelioma . Pharmacological Reports vol. 75 , ( 3 ) 753 - 753 .

Phillips MM, Pavlyk I, Allen M, Ghazaly E, Cutts R, Carpentier J, Berry JS, Nattress C et al. ( 2023 ) . A role for macrophages under cytokine control in mediating resistance to ADI-PEG20 (pegargiminase) in ASS1-deficient mesothelioma . Pharmacological Reports vol. 75 , ( 3 ) 570 - 584 .

Gonzalez-Pastor R, Hernandez Y, Gimeno M, de Martino A, Man YKS, Hallden G, Quintanilla M, de la Fuente JM et al. ( 2021 ) . Coating an adenovirus with functionalized gold nanoparticles favors uptake, intracellular trafficking and anti-cancer therapeutic efficacy . Acta Biomaterialia vol. 134 , 593 - 604 .

Stella Man YK, Foster J, Carapuça E, Davies JA, Parker AL, Sosabowski J, Halldén G ( 2019 ) . Systemic delivery and SPECT/CT in vivo imaging of 125I-labelled oncolytic adenoviral mutants in models of pancreatic cancer . Scientific Reports vol. 9 , ( 1 ) Article 12840 ,

Hallden G, Wang Y, Wong H-H, Lemoine NR ( 2019 ) . ONCOLYTIC ADENOVIRUSES FOR CANCER GENE THERAPY . Advanced Textbook on Gene Transfer, Gene Therapy and Genetic Pharmacology , WORLD SCIENTIFIC (EUROPE)

Hallden G ( 2019 ) . Improved replication and selectivity of oncolytic AdΔΔ and Ad-3Δ-A20T promotes targeting to distant lesions in preclinical pancreatic cancer models . HUMAN GENE THERAPY . vol. 30 , A7 - A8 .

Nattress CB, Halldén G ( 2018 ) . Advances in oncolytic adenovirus therapy for pancreatic cancer . Cancer Letters vol. 434 , 56 - 69 .

Baker A, Aguirre-Hernández C, Halldén G, Parker A ( 2018 ) . Designer Oncolytic Adenovirus: Coming of Age . Cancers vol. 10 , ( 6 ) 201 - 201 .

Man YKS, Davies JA, Coughlan L, Pantelidou C, Blázquez-Moreno A, Marshall JF, Parker AL, Halldén G ( 2018 ) . The Novel Oncolytic Adenoviral Mutant Ad5-3Δ-A20T Retargeted to αvβ6 Integrins Efficiently Eliminates Pancreatic Cancer Cells . Molecular Cancer Therapeutics vol. 17 , ( 2 ) 575 - 587 .

Aguirre-Hernández C, Maya-Pineda H, Millán JS, Man YKS, Lu Y-J, Halldén G ( 2018 ) . Sensitisation to mitoxantrone-induced apoptosis by the oncolytic adenovirus Ad∆∆ through Bcl-2-dependent attenuation of autophagy . Oncogenesis vol. 7 , ( 1 ) Article 6 ,

Aguirre-Hernandez C, Maya-Pineda H, Millan JS, Man YKS, Lu YJ, Hallden G ( 2017 ) . Sensitisation to mitoxantrone-induced apoptosis by the oncolytic adenovirus AdΔΔ through Bcl-2-dependent attenuation of autophagy . HUMAN GENE THERAPY . vol. 28 , A26 - A26 .

Hallden G ( 2017 ) . Targeting pancreatic and prostate cancer with E1B19K-deleted oncolytic adenoviruses . vol. 28 , is. 8 , pp. A6 - A6 .

Man YKS, Davies JA, Coughlan L, Pantelidou C, Marshall JF, Parker AL, Hallden G ( 2017 ) . The novel oncolytic adenoviral mutant Ad5-3Δ-A20T retargeted to αvβ6-integrins efficiently eliminates pancreatic cancer cells . HUMAN GENE THERAPY . vol. 28 , A27 - A27 .

Hallden G, Sweeney K ( 2016 ) . Oncolytic adenovirus-mediated therapy for prostate cancer . Oncolytic Virotherapy vol. Volume 5 , 45 - 57 .

Pantelidou C, Cherubini G, Lemoine NR, Halldén G ( 2016 ) . The E1B19K-deleted oncolytic adenovirus mutant AdΔ19K sensitizes pancreatic cancer cells to drug-induced DNA-damage by down-regulating Claspin and Mre11 . Oncotarget vol. 7 , ( 13 ) 15703 - 15724 .

Pantelidou C, Man YKS, Coughlan L, Marshall J, Kocher H, Hallden G ( 2016 ) . Oncolytic adenoviral mutants deleted in the anti-apoptotic E1B19K gene sensitize pancreatic cancer cells to drug-induced DNA damage . INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE vol. 38 , S58 - S58 .

Hernandez CA, Hallden G ( 2016 ) . The adenoviral AdDD mutant enhances mitoxantrone-induced cell death by promoting apoptosis and attenuating autophagy in prostate cancer cells . HUMAN GENE THERAPY . vol. 27 , A5 - A6 .

Aguirre-Hernandez C, Millan JS, Hallden G ( 2016 ) . The adenoviral AdΔΔ mutant enhances mitoxantrone-induced apoptosis and attenuates drug-induced autophagy in prostate cancer cells .

Pantelidou C, Hallden G ( 2015 ) . An oncolytic adenovirus (AdΔ19K) sensitizes pancreatic cancer cells to cytotoxic drugs by promoting DNA-damage and aberrant mitosis through inactivation of checkpoint mediators . HUMAN GENE THERAPY . vol. 26 , A19 - A20 .

Mercer EJ, Imrali A, Sharpe K, Hallden G, Lu Y-J ( 2014 ) . Abstract 713: Utilizing a potent and selective nonreplicating adenoviral mutant (Ad5-TV-CU), with gene expression controlled by androgen receptor-dependent activation domains in the TMPRSS2 gene, as a novel prodrug-converting enzyme therapy for prostate cancer . Cancer Research . vol. 74 , 713 - 713 .

Hallden G, Wang Y, Wong H-H, Lemoine NR ( 2014 ) . 18: ONCOLYTIC ADENOVIRUSES FOR CANCER GENE THERAPY . ICP Textbooks in Biomolecular Sciences , IMPERIAL COLLEGE PRESS

Pantelidou C, Lemoine N, Hallden G ( 2014 ) . Adenoviruses deleted in the anti-apoptotic E1B19K-gene synergise with DNA-damaging drugs through attenuation of DNA-damage repair responses and checkpoint activation in pancreatic cancer cells . HUMAN GENE THERAPY . vol. 25 , A17 - A17 .

Man YKS, Coughlan L, Pantelidou C, Hallden G ( 2014 ) . Oncolysis is greatly enhanced by retargeting of replication-selective adenoviral mutants to avβ6-integrin expressing cancers and in combination with cytotoxic drugs . HUMAN GENE THERAPY . vol. 25 , A18 - A18 .

Passaro C, Abagnale A, Libertini S, Volpe M, Botta G, Cella L, Pacelli R, Halldèn G et al. ( 2013 ) . Ionizing radiation enhances dl922–947-mediated cell death of anaplastic thyroid carcinoma cells . Endocrine-Related Cancer vol. 20 , ( 5 ) 633 - 647 .

Miranda E, Maya Pineda H, Öberg D, Cherubini G, Garate Z, Lemoine NR, Halldén G ( 2012 ) . Adenovirus-Mediated Sensitization to the Cytotoxic Drugs Docetaxel and Mitoxantrone Is Dependent on Regulatory Domains in the E1ACR1 Gene-Region . PLoS ONE vol. 7 , ( 10 ) e46617 - e46617 .

Adam V, Ekblad M, Sweeney K, Müller H, Busch KH, Johnsen CT, Kang NR, Lemoine NR et al. ( 2012 ) . Synergistic and Selective Cancer Cell Killing Mediated by the Oncolytic Adenoviral Mutant AdΔΔ and Dietary Phytochemicals in Prostate Cancer Models . Human Gene Therapy vol. 23 , ( 9 ) 1003 - 1015 .

Halldén G, Portella G ( 2012 ) . Oncolytic virotherapy with modified adenoviruses and novel therapeutic targets . Expert Opinion on Therapeutic Targets vol. 16 , ( 10 ) 945 - 958 .

Botta G, Passaro C, Libertini S, Abagnale A, Barbato S, Maione AS, Hallden G, Beguinot F et al. ( 2012 ) . Inhibition of Autophagy Enhances the Effects of E1A-Defective Oncolytic Adenovirus <i>dl</i>922–947 Against Glioma Cells <i>In Vitro</i> and <i>In Vivo</i> . Human Gene Therapy vol. 23 , ( 6 ) 623 - 634 .

Sweeney KG, Cheong SC, Lemoine NR, Hallden G ( 2012 ) . Abstract 2712: A non-replicating adenovirus expressing Hey1 is cytotoxic to prostate cancer cells . Cancer Research vol. 72 , ( 8_Supplement ) 2712 - 2712 .

Maya-Pineda HR, Miranda-Rota E, Lemoine NR, Halldén G ( 2012 ) . Abstract 2713: Adenovirus E1A binding to p300 is essential for synergistic cell killing in combination with chemotherapeutic drugs in prostate cancer cells . Cancer Research vol. 72 , ( 8_Supplement ) 2713 - 2713 .

Cherubini G, Kallin C, Mozetic A, Hammaren-Busch K, Müller H, Lemoine NR, Halldén G ( 2011 ) . The oncolytic adenovirus AdΔΔ enhances selective cancer cell killing in combination with DNA-damaging drugs in pancreatic cancer models . Gene Therapy vol. 18 , ( 12 ) 1157 - 1165 .

Bhattacharyya M, Francis J, Eddouadi A, Lemoine NR, Hallden G ( 2011 ) . An oncolytic adenovirus defective in pRb-binding (dl922-947) can efficiently eliminate pancreatic cancer cells and tumors in vivo in combination with 5-FU or gemcitabine . CANCER GENE THER vol. 18 , ( 10 ) 734 - 743 .

Halldén G ( 2011 ) . Adenoviral Gene Expression and Replication in Human Tumor Explant Models . 65 - 78 .

Sweeney K, Cheong SC, Lemoine N, Hallden G ( 2011 ) . A non-replicating adenovirus expressing Hey1 is cytotoxic to prostate cancer cells . HUMAN GENE THERAPY vol. 22 , ( 10 ) A122 - A122 .

Maya-Pineda H, Miranda E, Lemoine N, Hallden G ( 2011 ) . Adenovirus CIA binding to p300 is essential for synergistic cell killing in combination with chemotherapeutics in prostate cancer cells . HUMAN GENE THERAPY vol. 22 , ( 10 ) A104 - A104 .

Pantelidou C, Cherubini G, Lemoine NR, Hallden G ( 2011 ) . Adenovirus sensitizes pancreatic cancer cells to DNA-damaging chemotherapeutics through mitotic catastrophe induction and this is further enhanced by the deletion of the anti-apoptotic E1B19K gene . HUMAN GENE THERAPY vol. 22 , ( 10 ) A119 - A120 .

Ingemarsdotter CK, Baird SK, Connell CM, Oberg D, Hallden G, McNeish IA ( 2010 ) . Low-dose paclitaxel synergizes with oncolytic adenoviruses via mitotic slippage and apoptosis in ovarian cancer . ONCOGENE vol. 29 , ( 45 ) 6051 - 6063 .

Radhakrishnan S, Miranda E, Ekblad M, Holford A, Pizarro MT, Lemoine NR, Hallden G ( 2010 ) . Efficacy of Oncolytic Mutants Targeting pRb and p53 Pathways Is Synergistically Enhanced When Combined with Cytotoxic Drugs in Prostate Cancer Cells and Tumor Xenografts . HUM GENE THER vol. 21 , ( 10 ) 1311 - 1325 .

Ekblad M, Hallden G ( 2010 ) . Adenovirus-based therapy for prostate cancer . CURR OPIN MOL THER vol. 12 , ( 4 ) 421 - 431 .

Oberg D, Yanover E, Adam V, Sweeney K, Costas C, Lemoine NR, Hallden G ( 2010 ) . Improved Potency and Selectivity of an Oncolytic E1ACR2 and E1B19K Deleted Adenoviral Mutant in Prostate and Pancreatic Cancers . CLIN CANCER RES vol. 16 , ( 2 ) 541 - 553 .

Sweeney K, Cheong SC, Lemoine N, Hallden G ( 2010 ) . A non-replicating adenovirus expressing Hey1 is cytotoxic to prostate cancer cells . HUMAN GENE THERAPY . vol. 21 , 1398 - 1398 .

Ekblad M, Oberg D, Lemoine N, Hallden G ( 2010 ) . Development of an oncolytic adenovirus expressing the prodrug-converting enzyme CD/UPRT (AdΔΔCU) . HUMAN GENE THERAPY . vol. 21 , 1473 - 1473 .

Cherubini G, Kalllin C, Mozetic A, Hammaren-Busch K, Muller H, Lemoine N, Hallden G ( 2010 ) . Investigating a new potent and selective oncolytic adenovirus (AdΔΔ) in combination with chemotherapy . HUMAN GENE THERAPY . vol. 21 , 1473 - 1474 .

Lee M, Choi S, Hallden G, Yo SJ, Schichnes D, Aponte GW ( 2009 ) . P2Y5 is a G alpha(i), G alpha(12/13) G protein-coupled receptor activated by lysophosphatidic acid that reduces intestinal cell adhesion . AM J PHYSIOL-GASTR L vol. 297 , ( 4 ) G641 - G654 .

Leitner S, Sweeney K, Oberg D, Davies D, Miranda E, Lemoine NR, Hallden G ( 2009 ) . Oncolytic Adenoviral Mutants with E1B19K Gene Deletions Enhance Gemcitabine-induced Apoptosis in Pancreatic Carcinoma Cells and Anti-Tumor Efficacy In vivo . CLIN CANCER RES vol. 15 , ( 5 ) 1730 - 1740 .

Flak MB, Connell CM, Hill RM, Hallden G, Chelala C, McNeish IA ( 2009 ) . Critical Role for p21 and p27 in Efficacy of Oncolytic Adenovirus <i>dl</i>922-947 in Ovarian Cancer . MOLECULAR THERAPY . vol. 17 , S100 - S100 .

Hallden G ( 2009 ) . Optimisation of replication-selective oncolytic adenoviral mutants in combination with chemotherapeutics . JOURNAL OF BUON vol. 14 , S61 - S67 .

Adam V, Oberg D, Lemoine N, Hallden G ( 2009 ) . Prostate Cancer Targeting by Replication-Selective Adenoviral Mutants: Combination Treatments with Phytochemical Drugs . MOLECULAR THERAPY . vol. 17 , S320 - S320 .

Libertini S, Iacuzzo I, Perruolo G, Scala S, Ieranò C, Franco R, Hallden G, Portella G ( 2008 ) . Bevacizumab Increases Viral Distribution in Human Anaplastic Thyroid Carcinoma Xenografts and Enhances the Effects of E1A-Defective Adenovirus <i>dl</i>922-947 . Clinical Cancer Research vol. 14 , ( 20 ) 6505 - 6514 .

Bazan-Peregrino M, Carlisle RC, Hernandez-Alcoceba R, Iggo R, Homicsko K, Fisher KD, Hallden G, Mautner V et al. ( 2008 ) . Comparison of molecular strategies for breast cancer virotherapy using oncolytic adenovirus . HUM GENE THER vol. 19 , ( 9 ) 873 - 886 .

Bazan-Peregrino M, Carlisle R, Hernandez-Alcoceba R, Iggo R, Homicsko K, Hallden G, Mautner V, Shen J et al. ( 2008 ) . Comparison of Molecular Strategies for Breast Cancer Virotherapy using Oncolytic Adenovirus . Human Gene Therapy vol. 0 , ( ja ) 081015093227032 - 081015093227032 .

Cheong SC, Wang Y, Meng JH, Hill R, Sweeney K, Kirn D, Lemoine NR, Hallden G ( 2008 ) . E1A-expressing adenoviral E3B mutants act synergistically with chemotherapeutics in immunocompetent tumor models . CANCER GENE THER vol. 15 , ( 1 ) 40 - 50 .

Flak MB, Connell CM, Hill RM, Hallden G, Chelala C, McNeish IA ( 2008 ) . Host cell factors in ovarian cancer influencing efficacy of oncolytic adenovirus dl922-947 . HUMAN GENE THERAPY . vol. 19 , 1083 - 1083 .

Cheong SC, Oberg D, Nick L, Hallden G ( 2008 ) . Inhibition of late-stage prostate cancer using adenoviral mutants: Expression of an androgen receptor co-repressor and AR-siRNA . HUMAN GENE THERAPY . vol. 19 , 1082 - 1082 .

Adam VS, Lemoine N, Hallden G ( 2008 ) . Prostate cancer targeting by replication-selective adenoviral mutants: Combination treatments with phytochemical drugs . HUMAN GENE THERAPY . vol. 19 , 419 - 419 .

Adam V, Lemoine N, Hallden G ( 2008 ) . Prostate cancer targeting by replication-selective adenoviral mutants: combination treatments with phytochemical drugs . HUMAN GENE THERAPY . vol. 19 , 1165 - 1165 .

Gaballah K, Hills A, Curiel D, Hallden G, Harrison P, Partridge M ( 2007 ) . Lysis of Dysplastic but not Normal Oral Keratinocytes and Tissue-Engineered Epithelia with Conditionally Replicating Adenoviruses . Cancer Research vol. 67 , ( 15 ) 7284 - 7294 .

Choi S, Lee M, Shiu AL, Yo SJ, Halldén G, Aponte GW ( 2007 ) . GPR93 activation by protein hydrolysate induces CCK transcription and secretion in STC-1 cells . American Journal of Physiology-Gastrointestinal and Liver Physiology vol. 292 , ( 5 ) G1366 - G1375 .

Radhakrishnan S, Hallden GK, Chinegwundoh F, Lemoine N ( 2007 ) . 548: Synergistic Enhancement of Cell Death by Combination Therapy with Adenovirus and Chemotherapy . Journal of Urology . vol. 177 , 182 - 183 .

Cheong SC, Lemoine N, Hallden G ( 2007 ) . Inhibition of androgen receptor signaling pathways in prostate cancer cells by adenoviral vectors expressing Hey1 . HUMAN GENE THERAPY . vol. 18 , 1004 - 1004 .

Gaballah K, Partridge M, Hills A, Curiel D, Hallden G, Harrison P ( 2007 ) . Lysis of dysplastic but not normal organotypical oral epithelium with conditionally replicating adenoviruses . ORAL ONCOLOGY . 181 - 181 .

Radhakrishnan S, Hallden G, Chinegwundoh F, Lemoine N ( 2007 ) . Synergistic enhancement of prostate cancer cell death by combination therapy of adenovirus and chemotherapy . BJU INTERNATIONAL . vol. 99 , 28 - 28 .

Bapat U, Wang Y, Alusi G, Chisholm E, Francis J, Hallden G, Lemoine N ( 2006 ) . Oncolytic virotherapy for nasopharyngeal cancer . Clinical Otolaryngology vol. 31 , ( 6 ) 582 - 583 .

Bhattacharyya M, Hallden G, Francis J, Lemoine NR ( 2006 ) . Synergistic interactions between adenovirus and chemotherapy in pancreatic cancer cell lines: Effects of chemotherapy on expression of coxsackie-adenovirus receptor (CAR) and infectability by adenovirus . CANCER RESEARCH . vol. 66 ,

Liu TC, Wang Y, Hallden G, Brooks G, Francis J, Lemoine NR, Kirn D ( 2005 ) . Functional interactions of antiapoptotic proteins and tumor necrosis factor in the context of a replication-competent adenovirus . GENE THER vol. 12 , ( 17 ) 1333 - 1346 .

Wang YH, Xue SA, Hallden G, Francis J, Yuan M, Griffin BE, Lemoine NR ( 2005 ) . Virus-associated RNA I-deleted adenovirus, a potential oncolytic agent targeting EBV-associated tumors . CANCER RES vol. 65 , ( 4 ) 1523 - 1531 .

Lee M, Hadi M, Hallden G, Aponte GW ( 2005 ) . Peptide YY and neuropeptide Y induce villin expression, reduce adhesion, and enhance migration in small intestinal cells through the regulation of CD63, matrix metalloproteinase-3, and Cdc42 activity . J BIOL CHEM vol. 280 , ( 1 ) 125 - 136 .

Wang YH, Thorne S, Hanock J, Francis J, An T, Reid T, Lemoine N, Kirn D et al. ( 2005 ) . A novel assay to assess primary human cancer infectibility by replication-selective oncolytic adenoviruses . CLIN CANCER RES vol. 11 , ( 1 ) 351 - 360 .

Wang YH, Faux SP, Hallden G, Kirn DH, Houghton CE, Lemoine NR, Patrick G ( 2004 ) . Interleukin-1 beta and tumour necrosis factor-alpha promote the transformation of human immortalised mesothelial cells by erionite . INT J ONCOL vol. 25 , ( 1 ) 173 - 178 .

Liu TC, Hallden G, Wang YH, Brooks G, Francis J, Lemoine N, Kirn D ( 2004 ) . An E1B-19 kDa gene deletion mutant adenovirus demonstrates tumor necrosis factor-enhanced cancer selectivity and enhanced oncolytic potency . MOL THER vol. 9 , ( 6 ) 786 - 803 .

Hu J, Hallden G, Shorrock C, Simpson G, Coffin R, Kamalati T, Coombes R ( 2004 ) . Combination of a second generation genetically modified herpes simplex virus 1 (HSV 1) with paclitaxel in the treatment of breast cancer <i>in vitro</i> . MOLECULAR THERAPY . vol. 9 , S105 - S105 .

Hu JC, Hallden G, Shorrock C, Simpson G, Coffin R, Kamalati T, Coombes C ( 2004 ) . Combination of a second generation genetically modified herpes simplex virus 1 (HSV1) with paclitaxel in the treatment of breast cancer <i>in vitro</i> . JOURNAL OF CLINICAL ONCOLOGY . vol. 22 , 57S - 57S .

Hallden GK, Meng JH, Hill R, Wang YH, Francis J, Lemoine NN, Kirn DH ( 2004 ) . Combination therapy with adenovirus (Ad5) and cytotoxic drugs can act synergistically to induce cell death in carcinoma cell lines in culture . MOLECULAR THERAPY . vol. 9 , S113 - S113 .

Liu TC, Wang YH, Hallden G, Francis J, Brooks G, Lemoine N, Kirn D ( 2004 ) . Oncolytic adenovirus E1B-19kD deletion and E3B retention results in both enhanced potency and tumor necrosis factor-mediated selectivity . MOLECULAR THERAPY . vol. 9 , S109 - S109 .

Hill RJ, Hallden GK, Wang YH, Francis J, Simpson C, Kirn DH, Lemoine NR ( 2004 ) . The gene expression and function of adenoviral E3-genes in murine tumour cell lines . MOLECULAR THERAPY . vol. 9 , S374 - S375 .

Wang YH, Xue SA, Hallden G, Francis J, Griffin BE, Lemoine NR ( 2004 ) . VAI deleted adenovirus as an oncolytic agent targeting human EBV-associated tumours . MOLECULAR THERAPY . vol. 9 , S230 - S230 .

Wang YH, Hallden G, Hill R, Anand A, Liu TC, Francis J, Brooks G, Lemoine N et al. ( 2003 ) . E3 gene manipulations affect oncolytic adenovirus activity in immunocompetent tumor models . NAT BIOTECHNOL vol. 21 , ( 11 ) 1328 - 1335 .

Hallden G, Hill R, Wang YH, Anand A, Liu TC, Lemoine NR, Francis J, Hawkins L et al. ( 2003 ) . Novel immunocompetent murine tumor models for the assessment of replication-competent oncolytic adenovirus efficacy . MOL THER vol. 8 , ( 3 ) 412 - 424 .

Hill RJ, Hallden GK, Lemoine NR, Kirn DH ( 2003 ) . <i>In vitro</i> screening of murine carcinoma cell lines for testing of replication-competent oncolytic adenoviruses . MOLECULAR THERAPY . vol. 7 , S362 - S362 .

Liu TC, Wang YH, Hallden G, Anand A, Lemoine NR, Kirn DH ( 2003 ) . Adenoviral E1B-19kD deletion results in enhanced oncolytic effect and reduced toxicity in an immunocompetent murine tumor . MOLECULAR THERAPY . vol. 7 , S416 - S416 .

Liu TC, Hallden G, Anand A, Wang YH, Lemoine N, Kirn D ( 2003 ) . Adenovirus E1B-19kD gene deletion enhances oncolytic virus efficacy and selectivity . CANCER GENE THERAPY . vol. 10 , S20 - S20 .

Kirn D, Niculescu-Duvaz I, Hallden G, Springer CJ ( 2002 ) . The emerging fields of suicide gene therapy and virotherapy . TRENDS MOL MED vol. 8 , ( 4 ) S68 - S73 .

Hallden G, Holehouse EL, Dong X, Aponte GW ( 1994 ) . Expression of intestinal fatty acid binding protein in intestinal epithelial cell lines, hBRIE 380 cells . American Journal of Physiology-Gastrointestinal and Liver Physiology vol. 267 , ( 4 ) G730 - G743 .

Mulvihill SJ, Hallden G, Debas HT ( 1989 ) . Trophic effect of amniotic fluid on cultured fetal gastric mucosal cells . Journal of Surgical Research vol. 46 , ( 4 ) 327 - 329 .

Szecowka J, Hallden G, Goldfine ID, Williams JA ( 1989 ) . Purification of the pancreatic cholecystokinin receptor . Regulatory Peptides vol. 24 , ( 3 ) 215 - 224 .

Halldén G, Thorne SH, Yang J, Kirn DH . Replication-Selective Oncolytic Adenoviruses . 71 - 90 .